Trials and papersGastric & gastro-oesophageal junction cancer

This is the registry reading itself, and it is the source every Korean cancer figure on OnCo should be traced to. It shows a country where incidence is still rising with age while death rates keep falling, and where most of the survival gain comes from finding cancers earlier.

For someone offered the test, these are the numbers that describe what a result means in an NHS population: about 1 in 100 tests came back positive each year, between 46 and 58 in 100 positives were cancer, and a negative result left about 1 in 100 with an undetected cancer within the year. The test found between a quarter and a third of all cancers diagnosed in a screening round, and about half to two thirds of the 12 cancer types it was designed to find. Whether finding them this way reduces late-stage diagnoses is the primary question, and this paper says only that the answer was no; the primary-endpoint paper had not appeared on Europe PMC by 23 September 2026.

This is the trial behind the first approval of a CAR-T therapy for a solid tumour, in China. The gain in progression-free survival is real but measured in weeks, 15 percent of patients randomised to satri-cel never received it, and nearly every treated patient had cytokine release syndrome, so the trade-off is very different from CAR-T in blood cancers. Overall survival is not reported in the abstract.

Every insured Korean adult from 40 is offered a stomach endoscopy every two years, and people at high risk of liver cancer an ultrasound and blood test every six months. This review, by the researchers who run the programme, sets out how that came about.

Strong figures in hospital patients, but at about 94 to 96% specificity roughly one in twenty people without cancer would test positive, too many for screening healthy people without a second test.

The most recent full national incidence report from the registry that OnCo could read in full. It shows prostate cancer overtaking stomach cancer in men since 2014 and a large number of non-melanoma skin cancers, which change totals depending on whether they are counted.

A residual disease test built on clonal variants only, which detects the trunk of the tumour and by design not its branches.

Patients with newly diagnosed advanced stomach cancer should now have Claudin 18.2 tested alongside HER2, PD-L1 and mismatch repair, because roughly a third will be eligible for zolbetuximab, which adds about three months of median survival. The main practical problem is nausea and vomiting during infusions, which needs aggressive prophylaxis. How to sequence or combine it with immunotherapy in PD-L1-positive tumours is unresolved.